Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Policy Update: Extrapolation Looks Like Default Approach

This article was originally published in RPM Report

Executive Summary

As FDA nears the first review deadlines for biosimilar applications, some policy points are coming into sharper focus. Clinical studies for immunogenicity sound like a benchmark requirement, while extrapolation of indications also seems like the agency’s default position.

You may also be interested in...



Will 2016 Be The Year of the Biosimilar?

The first wave of biosimilars seemed ready to come to market in 2015, but only one product actually made it through FDA. The coming year might be the year when multiple biosimilars enter the US.

Will 2016 Be The Year of the Biosimilar?

The first wave of biosimilars seemed ready to come to market in 2015, but only one product actually made it through FDA. The coming year might be the year when multiple biosimilars enter the US.

Words Of Wisdom For Biosimilar Developers

FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel